Intercept Pharm (ICPT) Posts Q2 Loss of 79c/Share; Issues Positive FLINT Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Intercept Pharm (ICPT) Posts Q2 Loss of 79c/Share; Issues Positive FLINT Data

Intercept Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business Update

August 11, 2014 4:15 PM EDT

NEW YORK, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today reported financial results for the quarter and six months ended June 30, 2014 and provided other general business updates including additional data from the FLINT trial in NASH patients. These results are included in Intercept's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission. Intercept will hold a conference call and audio... More